Keyphrases
Erlotinib
100%
Epidermal Growth Factor Receptor
100%
Mitogen-activated Protein Kinase
100%
HepG2
100%
ABC Transporter Inhibitors
100%
P-glycoprotein (P-gp)
75%
Multidrug Resistance-associated Protein 2 (MRP2)
75%
ATP-binding Cassette Transporter A1 (ABCA1)
50%
IC50 Value
50%
Western Blot Analysis
50%
Multidrug Resistance Protein 1 (MDR1)
50%
MK571
50%
Combination Therapy
25%
Drug Resistance
25%
Molecular Dynamics Simulation
25%
Hepatocellular Carcinoma
25%
Cell Migration
25%
ABCG2
25%
Cancer Mortality
25%
Cancer Causes
25%
HepG2 Cells
25%
Cell Cycle Arrest
25%
Survivability
25%
Estrone
25%
G2 Phase
25%
Hepatocellular Carcinoma Cells
25%
Epidermal Growth Factor Receptor Inhibitors
25%
Line Resistance
25%
Combinatorial Study
25%
MEK Kinase
25%
Pharmacology, Toxicology and Pharmaceutical Science
P-Glycoprotein
100%
Multidrug Resistance-Associated Protein 2
100%
Phosphotransferase
100%
ABC Transporter
100%
Epidermal Growth Factor Receptor
100%
Erlotinib
100%
Western Blot
66%
Liver Cell Carcinoma
66%
Multidrug Resistance Associated Protein 1
66%
IC50
66%
ABCG2
33%
Cancer Mortality
33%
Lead Compound
33%
Epidermal Growth Factor Receptor Kinase Inhibitor
33%
Combination Therapy
33%
Drug Resistance
33%
Estrone
33%